Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EBT Margin for 9 consecutive years, with 18346.35% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBT Margin fell 1691431.0% year-over-year to 18346.35%, compared with a TTM value of 51942.19% through Sep 2025, down 5097060.0%, and an annual FY2024 reading of 7939.91%, down 630114.0% over the prior year.
  • EBT Margin was 18346.35% for Q4 2024 at Avalo Therapeutics, down from 9246.18% in the prior quarter.
  • Across five years, EBT Margin topped out at 9246.18% in Q3 2024 and bottomed at 18346.35% in Q4 2024.
  • Average EBT Margin over 5 years is 2305.41%, with a median of 1265.9% recorded in 2023.
  • Peak annual rise in EBT Margin hit 1145805bps in 2024, while the deepest fall reached -1691431bps in 2024.
  • Year by year, EBT Margin stood at 1091.02% in 2020, then tumbled by -701bps to 8742.92% in 2021, then skyrocketed by 87bps to 1094.2% in 2022, then crashed by -31bps to 1432.05% in 2023, then tumbled by -1181bps to 18346.35% in 2024.
  • Business Quant data shows EBT Margin for AVTX at 18346.35% in Q4 2024, 9246.18% in Q3 2024, and 1432.05% in Q4 2023.